{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:20:07Z","timestamp":1768530007980,"version":"3.49.0"},"reference-count":51,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Objective: We aimed to evaluate the use of CDK4\/6 inhibitors as a risk factor for medication-related osteonecrosis of the jaw (MRONJ) in a cohort of patients with metastatic breast cancer treated with denosumab. Methods: This was a multicentre, retrospective, observational study. All patients with breast cancer treated with denosumab (January 2011\u2013December 2022) were included. The relationship between CDK4\/6 inhibitors and MRONJ was analysed. Results: A total of 243 patients were included, ninety-five (44.2%) of whom used a CDK4\/6 inhibitor. There were 21 patients with MRONJ. In patients treated with denosumab without CDK4\/6 inhibitors, the incidence of MRONJ and mean time to the occurrence of MRONJ were 6.6% (8\/120) and 16.8 months (SD 7.8), respectively; in patients treated with denosumab and CDK4\/6 inhibitor, these values were 13.7% (13\/95) and 15.4 months (SD 8.7), respectively. The difference in the incidence was not significant (p = 0.085). Among the 19 patients who used abemaciclib, the probability of MRONJ occurrence was significantly higher compared to patients not using CDK4\/6 inhibitors (p = 0.0178). Conclusions: These results suggest that the incidence of MRONJ in patients with metastatic breast cancer treated with denosumab is higher, and the onset of MRONJ occurs earlier in the presence of CDK4\/6 inhibitors. The differences were statistically significant in the patients who used abemaciclib. Given that the use of this combination is very common in routine clinical practice, it would be advisable to carry out larger prospective studies to clarify the risk of this association.<\/jats:p>","DOI":"10.3390\/curroncol31010016","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T06:04:09Z","timestamp":1704175449000},"page":"250-259","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4\/6 Inhibitors in Breast Cancer"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7931-8358","authenticated-orcid":false,"given":"Loreto Dom\u00ednguez","family":"Sen\u00edn","sequence":"first","affiliation":[{"name":"Hospital Pharmacy, Juan Ram\u00f3n Jim\u00e9nez University Hospital, 21005 Huelva, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Morales","family":"Pancorbo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Juan Ram\u00f3n Jim\u00e9nez University Hospital, 21005 Huelva, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Yeray Rodr\u00edguez","family":"Garc\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Riotinto Hospital, 21660 Huelva, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Santos-Rubio","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Juan Ram\u00f3n Jim\u00e9nez University Hospital, 21005 Huelva, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Bayo","family":"Calero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Juan Ram\u00f3n Jim\u00e9nez University Hospital, 21005 Huelva, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S1470-2045(08)70305-X","article-title":"Pharmacovigilance and reporting oversight in US FDA fast-track process: Bisphosphonates and osteonecrosis of the jaw","volume":"9","author":"Edwards","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_2","unstructured":"Amgen Inc (2023, August 02). Xgeva (Denosumab) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125320s094lbl.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0076","article-title":"NCCN Task Force Report: Bone Health in Cancer Care","volume":"7","author":"Gralow","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: Mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9640","DOI":"10.1200\/jco.2013.31.15_suppl.9640","article-title":"Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials","volume":"31","author":"Lipton","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: A meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/njms.NJMS_236_20","article-title":"Medication-related osteonecrosis of the jaw: An update","volume":"13","author":"Bansal","year":"2022","journal-title":"Natl. J. Maxillofac. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-Related Osteonecrosis of the Jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ncponc1000","article-title":"Bisphosphonates and osteomyelitis of the jaw: A pathogenic puzzle","volume":"4","author":"Bertoldo","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","article-title":"Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw","volume":"14","author":"Raje","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1634\/theoncologist.2008-0209","article-title":"Bisphosphonates in oncology: Rising stars or fallen heroes","volume":"14","author":"Huizing","year":"2009","journal-title":"Oncologist"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-09-0426","article-title":"High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties","volume":"15","author":"Pozzi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.11607\/jomi.te41","article-title":"A review of pharmaceutical agents and oral bone health: How osteonecrosis of the jaw has affected the field","volume":"29","author":"Allen","year":"2014","journal-title":"Int. J. Oral Maxillofac. Implant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1634\/theoncologist.2008-0091","article-title":"Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy","volume":"13","author":"Estilo","year":"2008","journal-title":"Oncologist"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","article-title":"Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series","volume":"123","author":"Fedele","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/hed.21708","article-title":"Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws","volume":"34","author":"Wutzl","year":"2012","journal-title":"Head Neck"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.joms.2014.07.012","article-title":"Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: A pooled case report analysis","volume":"73","author":"Hinson","year":"2015","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Marcian\u00f2, A., Guzzo, G.M., Peditto, M., Picone, A., and Oteri, G. (2020). Medication-Related Osteonecrosis of the Jaws and CDK4\/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17249509"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jso.2930230311","article-title":"Breast carcinoma: Pattern of metastasis at autopsy","volume":"23","author":"Lee","year":"1983","journal-title":"J. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1177\/10781552231165434","article-title":"Osteonecrosis of the jaw under palbociclib: A case series description","volume":"29","author":"Yosofi","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/14737140.2017.1355242","article-title":"Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: A systematic review and meta-analysis","volume":"17","author":"Lasheen","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination with Fulvestrant inWomen with HR+\/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Basile, D., Di Nardo, P., Corvaja, C., Garattini, S.K., Pelizzari, G., Lisanti, C., Bortot, L., Da Ros, L., Bartoletti, M., and Borghi, M. (2019). Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers, 11.","DOI":"10.3390\/cancers11060857"},{"key":"ref_34","first-page":"9509","article-title":"Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4\/6 Inhibitors? A Word of Cautiousness. Comment on Marcian\u00f2 et al. Medication-Related Osteonecrosis of the Jaws and CDK4\/6 Inhibitors: A Recent Association","volume":"17","author":"Fusco","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: Results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_38","unstructured":"(2023, August 02). Encuesta Europea de Salud en Espa\u00f1a 2020. Available online: https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/EncuestaEuropeaEnc_Eur_Salud_en_Esp_2020_datos.htm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","volume":"35","author":"Somerfield","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JOP.17.00013","article-title":"Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary","volume":"14","author":"Anderson","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1634\/theoncologist.2008-0206","article-title":"Osteonecrosis of the jaw and the use of antiangiogenic agents: Just an association?","volume":"13","author":"Dahut","year":"2008","journal-title":"Oncologist"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Ning","year":"2009","journal-title":"Cancer Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: Presentation of three cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-017-3903-5","article-title":"Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"26","author":"Loyson","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: A systematic review","volume":"27","author":"Kouri","year":"2019","journal-title":"Support. Care Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/1\/16\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:37:49Z","timestamp":1760103469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/1\/16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["curroncol31010016"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31010016","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}